Ranibizumab FDA Link

A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.

Also Known As:

Lucentis; RhuFab V2; V2, RhuFab

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Ranibizumab: 3292
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Ranibizumab: 3292
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Ranibizumab: 3292

Swee Sew Teh Selected Research

Swee Sew Teh Research Topics

Disease

Drug/Important Bio-Agent (IBA)